Issue 26, 2023, Issue in Progress
From the journal:

RSC Advances

Correction: FDPP–HA as a theranostic agent for cancer-targeted fluorescence imaging and photodynamic therapy

Pingping Liang,a   Jinjun Shao,a   Qianyun Tang,a   Weili Si,*a   Qiang Wang,c   Qi Zhang*b  and  Xiaochen Dong*a  

* Corresponding authors

a Key Laboratory of Flexible Electronics (KLOFE), Institute of Advanced Materials (IAM), Jiangsu National Synergetic Innovation Center for Advanced Materials (SICAM), Nanjing Tech University (NanjingTech), Nanjing, China
E-mail: iamxcdong@njtech.edu.cn

b School of Pharmaceutical Sciences, Nanjing Tech University (NanjingTech), Nanjing, China
E-mail: zhangqi@njtech.edu.cn

c College of Chemistry and Molecular Engineering, Nanjing Tech University (NanjingTech), Nanjing, China

Abstract

Correction for ‘FDPP–HA as a theranostic agent for cancer-targeted fluorescence imaging and photodynamic therapy’ by Pingping Liang et al., RSC Adv., 2017, 7, 37369–37373, https://doi.org/10.1039/C7RA06551E.

About
Cited by
Related
Download options Please wait...

Associated articles

Article information

DOI
https://doi.org/10.1039/D3RA90050A
Article type
Correction
Submitted
01 Jun 2023
Accepted
01 Jun 2023
First published
12 Jun 2023
This article is Open Access
Creative Commons BY license

RSC Adv., 2023,13, 17621-17621

Permissions

Request permissions

Correction: FDPP–HA as a theranostic agent for cancer-targeted fluorescence imaging and photodynamic therapy

P. Liang, J. Shao, Q. Tang, W. Si, Q. Wang, Q. Zhang and X. Dong, RSC Adv., 2023, 13, 17621 DOI: 10.1039/D3RA90050A

This article is licensed under a Creative Commons Attribution 3.0 Unported Licence. You can use material from this article in other publications without requesting further permissions from the RSC, provided that the correct acknowledgement is given.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements